JAK-STAT pathway inhibitors in dermatology
An. bras. dermatol
; 98(5): 656-677, 2023. tab, graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1505662
Responsible library:
BR1.1
ABSTRACT
Abstract The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice.
Full text:
Available
Collection:
International databases
Database:
LILACS
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2023
Document type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Faculdade de Medicina do ABC/BR
/
Hospital de Dermatologia Sanitária do Paraná/BR
/
Universidade Estadual Paulista/BR
/
Universidade Federal de Goiás/BR
/
Universidade do Estado do Amazonas/BR